Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nonmyeloablative BMT With Post-transplant Cyclophosphamide, Rituximab and Optimized Donor Selection for B-cell Lymphomas

Next Previous
Trial Profile

Nonmyeloablative BMT With Post-transplant Cyclophosphamide, Rituximab and Optimized Donor Selection for B-cell Lymphomas

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Rituximab (Primary) ; Mycophenolate mofetil; Tacrolimus
  • Indications B-cell lymphoma; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Graft-versus-host disease; Hairy cell leukaemia; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use

Most Recent Events

  • 23 Sep 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
  • 09 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
  • 28 Sep 2012 Planned number of patients changed from 55 to 150 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top